

<ロト <四ト <注入 <注下 <注下 <

Framework and practical tool for eliciting expert priors in clinical trials with MNAR outcomes

Alexina Mason

joint work with James Carpenter, Richard Grieve and Manuel Gomes

> Centre for Statistical Methodology Seminar 26 October 2018

Framework

Elicitation Tool

Results and Discussion

▲□▶ ▲□▶ ▲□▶ ▲□▶ = 三 のへで



Introduction Background Illustrations

Framework

Elicitation Tool

Results and Discussion

Framework

Elicitation Tool

Results and Discussion

()

Background

- Missing data in RCTs can lead to
 - underestimation of uncertainty
 - biased effectiveness estimates
- The analysis of RCTs typically assumes outcomes are 'missing at random' (MAR)
 - probability of observing outcome does not depend on patient's outcome, after conditioning on the observed data
- However, concern MAR may be implausible in many settings
 - in particular for patient-reported outcomes, e.g. quality of life
- So, methodological guidelines recommend sensitivity analysis recognising data could be 'missing not at random' (MNAR)
- But, recently Bell et al. (2014)
 - reviewed 77 RCTS published in prestigious medical journals
 - found none conducted MNAR sensitivity analysis

Framework

Elicitation Tool

Results and Discussion

A D F A 同 F A E F A E F A Q A

Aims of this research

- Why is MNAR sensitivity analysis not performed?
- Requires specifying plausible assumptions a challenge!
- Elicited expert opinion can help frame relevant MNAR scenarios
- OUR AIM: to encourage triallists to conduct MNAR sensitivity analyses by providing
 - a framework for eliciting expert opinion about MNAR outcomes in clinical trials
 - a practical, easy-to-use, elicitation tool
- We have developed these using two typical trials
 - IMPROVE
 - POPPI

Elicitation Tool

Results and Discussion

Illustration 1: the IMPROVE trial

- Aim of the IMPROVE trial (Grieve *et al.*, 2015)
 - to assess the effectiveness of an emergency endovascular strategy (eEVAR) compared with open repair (OPEN) to treat patients with a ruptured abdominal aortic aneurysm
- Pragmatic, parallel design, multi-centre RCT (30 sites, N=613)
- Outcomes included quality of life (QoL) at 3 months
 - measured using the EQ-5D-3L health questionnaire
- Primary analysis found a clinically significant difference favouring eEVAR
- 21% of surviving patients did not complete EQ-5D-3L questionnaire at 3 months
 - primary analysis used multiple imputation assuming MAR
 - unclear whether gains depend on the assumptions about the missing data

Elicitation Tool

Results and Discussion

Illustration 2: the POPPI trial

- Aim of the POPPI trial
 - to investigate whether a complex psychological intervention, commenced early in ICU, would reduce patient-reported PTSD symptom severity
- Parallel design, multi-centre, cluster RCT (24 sites, N=1,458)
- Two important outcomes collected by self report questionnaire at 6 months
 - Primary outcome: patient-reported PTSD symptom severity, measured using the PTSD Symptom Scale (PSS-SR)
 - Health-related quality of life, measured using the EQ-5D-5L health questionnaire (HrQoL)
- Loss to follow-up anticipated to be 20% among survivors
- Statistical analysis plan specified
 - primary analysis using multiple imputation assuming MAR
 - MNAR sensitivity analysis informed by expert opinion

Framework

Elicitation Tool

Results and Discussion

Framework overview



Framework

Results and Discussion

Framework: Step 1 - Specify Statistical Models



▲□▶▲□▶▲□▶▲□▶ □ のへ⊙

Framework

Elicitation Tool

Results and Discussion

(日) (日) (日) (日) (日) (日) (日)

Joint models

• Notation:

- Let $\mathbf{z} = (z_{ij})$ denote a rectangular data set of interest i = 1, ..., n individuals and j = 1, ..., k variables
- Let $\mathbf{m} = (m_{ij})$ be a binary indicator variable such that $m_{ij} = \begin{cases} 0: & z_{ij} & \text{observed} \\ 1: & z_{ij} & \text{missing} \end{cases}$
- Let β and θ denote vectors of unknown parameters
- Then the joint model (likelihood) of the full data is $f(\boldsymbol{z}, \boldsymbol{m}|\beta, \theta)$
- MNAR requires modelling
 - 1. data of interest
 - 2. missing data mechanism

Elicitation Tool

Results and Discussion

Pattern mixture models

- Two factorisations of the joint model are commonly used
 - 1. selection models

 $f(\boldsymbol{z}, \boldsymbol{m}|\boldsymbol{\beta}, \boldsymbol{\theta}) = f(\boldsymbol{m}|\boldsymbol{z}, \boldsymbol{\beta}, \boldsymbol{\theta})f(\boldsymbol{z}|\boldsymbol{\beta}, \boldsymbol{\theta})$

2. pattern mixture models

 $f(\boldsymbol{z}, \boldsymbol{m}|\boldsymbol{\beta}, \boldsymbol{\theta}) = f(\boldsymbol{z}|\boldsymbol{m}, \boldsymbol{\beta}, \boldsymbol{\theta})f(\boldsymbol{m}|\boldsymbol{\beta}, \boldsymbol{\theta})$

see Molenberghs et al. (2015) for further details

- We have chosen to use pattern mixture models
 - allow a different model for z for each pattern of missing values
 - assumptions about the missing data are more explicit
 - corresponds more directly to what is actually observed (i.e. the distribution of the data within subgroups having different missing data patterns)

(ロ) (同) (三) (三) (三) (○) (○)

Estimating a treatment difference using a PMM

Example from the IMPROVE trial



 μ = mean QoL for patients who returned their QoL questionnaires

 δ = difference in mean QoL between patients with observed and missing QoL π = proportion of patients with missing QoL

E = eEVAR treatment group; O = open repair treatment group

Elicitation Tool

Results and Discussion

(日) (日) (日) (日) (日) (日) (日)

Pattern mixture model equations (IMPROVE)

Pattern 1: patients who completed their QoL questionnaire:

 $QoL_{i} \sim N(\mu_{i}, \sigma^{2})$ $\mu_{i} = \eta_{t(i)} + \beta_{a}age_{i} + \beta_{s}sex_{i} + \beta_{h,hardman(i)}$

 $\eta_1, \eta_2, \beta_a, \beta_s, \beta_{h,1}, \dots, \beta_{h,5}, \sigma^2 \sim \text{prior distribution}$

t(i) trial arm indicator of individual i

age and sex are fully observed

Hardman index (hardman) is partially observed

⇒ covariate imputation model required

Pattern 2: patients who did not complete their QoL questionnaire: $\mu_i = \eta_{t(i)} + \delta_{t(i)} + \beta_a age_i + \beta_s sex_i + \beta_{h,hardman(i)}$

Framework

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

What information is required from experts?

- δ are unidentifiable sensitivity parameters
 - relate to difference in mean score between patients who did and did not return their questionnaire
- Comparisons made for patients who are similar according to observed characteristics
- To convert expert opinion about this difference into an informative prior, we must elicit
 - 1. the value that the expert believes is most likely
 - 2. the expert's uncertainty about this value

◆□▶ ◆□▶ ▲□▶ ▲□▶ ■ ののの

What information should be elicited from experts?

- In the context of a typical RCT, require
 - estimates by randomised arm
 - estimate of the correlation between treatment arms
- Allows specification of a joint prior
- For IMPROVE, we elicited the difference in mean QoL score for patients who did NOT return their questionnaire compared to those whose questionnaire was returned for:
 - 1. patients in OPEN REPAIR arm (marginal distribution)
 - 2. patients in eEVAR arm (marginal distribution)
 - 3. patients in eEVAR arm given the difference in the OPEN REPAIR arm (conditional distribution)

Framework

Elicitation Tool

Results and Discussion

Framework: Step 2 - Prepare Elicitation Tool



◆□▶ ◆□▶ ◆三▶ ◆三▶ ・三 のへで

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Step 2: Presentation of Outcome Scales

- Can develop easy-to-use web based elicitation tool using Shiny
 - a web application framework within the statistical software, R
- Adopting a graphical approach
 - helps experts represents their views intuitively
 - naturally produces prior distributions for statistical models
- Outcome scales
 - must be interpretable to non-statistical expert
 - can be customised using descriptive labels and/or examples
- Examples shortly

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ ■ ののの

Step 2: Representation of Expert Opinion

- Tension between
 - sufficient flexibility to represent expert beliefs accurately and
 - over-complicating the elicitation exercise and subsequent analysis
- In broad terms, choice is
 - parametric distributions, e.g. normal distribution, often calculated from elicited quantiles
 - non-parametric distributions, typically represented as a histogram and elicited using 'chips and bins'
- What shapes could distributions representing expert uncertainty realistically take?
 - individual scores plausibly bimodal 'too sick' and 'too well' may not respond
 - but expert's uncertainty about average scores will be uni-modal
- Other considerations bounded scales

Framework

Elicitation Tool

Results and Discussion

Step 2: Outcome scale for PSS-SR scores



Framework

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Step 2: Other important elements

- Characterisation of patient population
 - is the patient population homogeneous?
 - should we elicit by sub-group?
- Defining elicitation questions
 - consider structure, wording, use of feedback
 - crucial wording ensures expert provides views about average, not individual scores
 - include free text questions useful for assessment
- Expert training do the experts
 - understand the elicitation tasks?
 - correctly interpret the graphics?



|▲□▶ ▲圖▶ ▲≣▶ ▲≣▶ | ≣ | のへで



Report Results

(日) (空) (日) (日) (日) (日)

Elicitation Tool

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Step 4: Recruit Experts and Conduct Elicitation

- Recruit Experts
 - require good coverage of experts with interest in the research questions
 - identify experts with relevant knowledge about trial outcomes, beyond that recorded in the data
 - chief investigator emails participation invitation to potential respondents
- Conduct Elicitation
 - in-person (conference breaks) or remote (send web link)
 - consent taken electronically
 - reminders emailed

Framework

Elicitation Tool

Results and Discussion

Framework: Step 5 - Analyse Elicitation Results



▲□▶▲□▶▲□▶▲□▶ □ のへ⊙

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ ■ ののの

Step 5: Strategy for non-elicited subgroups

- Following issues considered in Step 2
 - Should we elicit by subgroup?
 - If so, how should we define the subgroups?
 - If impractical to elicit for all subgroups, which should we choose?
- How should we treat non-elicited subgroups?
 - assign a prior or mixture of priors from elicited subgroups
 - assume a priori observed differences in distributions of sub-groups carry through to differences in the priors
- How should we deal with subgroup correlation?

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Step 5: Assessment of Elicitation Results - Cooke

- Crucial question: do the experts understand the questions?
- Colson and Cooke (2018):

validation of expert judgements means both that the judgements reflect the beliefs of the expert and that those beliefs reflect reality

- Cooke's 'classical' method compares elicited judgements to observed data using seed (calibration) questions
- Finding suitable seed questions
 - recognised as difficult
 - adds substantially to demands on experts' time

troduction Framew

Framework

Elicitation Tool o Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Step 5: Assessment of Elicitation Results - alternative

- Use criteria based on a combination of the experts' quantitative and qualitative responses to identify:
 - experts who have provided 'usable' responses
 - subgroup in whom we have 'high confidence'
- 'usable' experts
 - exclude experts who clearly misunderstood the task
 - multiple unmoved sliders or evidence from qualitative responses
- 'high confidence' experts
 - evidence of high level of engagement with elicitation exercise from qualitative answers
 - consistency between quantitative and qualitative answers
 - consistency in approach to all subgroups

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Step 5: Selection of Individual Priors and Synthesis of Expert Opinion

- Individual priors:
 - choose to reflect diversity of opinion
 - e.g. 'most enthusiastic' and 'most sceptical'
- Pooled priors:
 - average of individual distributions for multiple experts
 - linear pooling, with equal weights
 - specified as a mixture of distributions
 - e.g. all 'high confidence' experts, all doctors



▲□▶▲圖▶▲≣▶▲≣▶ ≣ の�?



◆□▶ ◆□▶ ◆臣▶ ◆臣▶ ─臣 ─のへで

Framework

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ◆臣▶ ◆臣▶ ─臣 ─のへで

Elicitation Tool DEMO

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

The experts

- IMPROVE:
 - 46 potential experts, with ongoing trial involvement, identified
 - principal investigators (mainly consultant vascular surgeons)
 - trial co-ordinators (vascular nurse specialists or research nurses)
 - 26 responses submitted, 15 at conference (The Vascular Society Annual Scientific Meeting in November 2015)

Framework

Elicitation Tool

Results and Discussion

IMPROVE: individual expert priors



- Elicited QoL scores for patients with missing data lower on average than observed QoL scores
- But considerable uncertainty in these elicited values

Framework

Elicitation Tool

Results and Discussion

・ ロ ト ・ 雪 ト ・ 雪 ト ・ 日 ト

3

IMPROVE: pooled marginal distributions



- Views of all experts combined using mathematical aggregation
 - linear pooling with equal weights
 - mixture of normal distributions

Framework

Elicitation Tool

Results and Discussion

< □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □

IMPROVE: joint pooled prior



Allows values in the two arms to be related

Framework

Elicitation Tool

Results and Discussion

IMPROVE: difference in mean QoL at 3 months

Probability of finding a clinically relevant difference in mean QoL between arms*

Posterior distribution with mean and 95% CI marked



*0.03 is considered the minimum clinically important difference (Walters and Brazier, 2005)

Framework

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ ■ ののの

Comment

- Successfully demonstrated a practical approach for
 - eliciting expert opinion from a range of experts
 - conducting MNAR sensitivity analysis
- Allows more realistic assumptions to be made about the missing data
- It allows us to quantify how experts would interpret the study
 - taking into account their understanding of the differences between the observed and missing values
- Models naturally extend to more complex settings

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Challenges and extensions

- Address concerns raised by Heitjan (2017)
 - evaluate framework using structured qualitative interviews
 - improve training and feedback
 - extend approach to assessment of elicitation results
- Extension to multiple time-points
 - number of sensitivity parameters can quickly become large with increasing time-points
 - simplifying assumptions may be required focus on key parameters
 - discuss with subject-matter experts which parameters are most relevant
- Sub-groups best strategy unclear
- Generalise to other types of trials and endpoints

Framework

Elicitation Tool

Results and Discussion

◆□▶ ◆□▶ ▲□▶ ▲□▶ □ のQ@

Acknowledgements

- Pinar Ulug (IMPROVE Trial Manager) and Janet Powell (IMPROVE Chief Investigator)
- David Harrison, Paul Mouncey, Alvin Richards-Belle and Kathy Rowan (ICNARC)
- All the IMPROVE and POPPI 'Experts' who made this research possible
- LSHTM staff who assisted with pre-piloting

Besults and Discussion 00000000 References Bell, M. L., Fiero, M., Horton, N. J., and Hsu, C.-H. (2014). Handling missing data in RCTs; a review of the top medical journals. BMC Medical Research Methodology, 14, 118. Colson, A. R. and Cooke, R. M. (2018). Expert Elicitation: Using the Classical Model to Validate Experts' Judgments. Review of Environmental Economics and Policy, 12, (1), 113-32. Grieve, R., Gomes, M., Sweeting, M. J., Ulug, P., Hinchliffe, R. J., Thompson, M. M., Thompson, S. G., Ashleigh, R., Greenhalgh, R. M., and Powell, J. T. (2015). Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial. European Heart Journal, 36, (31), 2061-9. Heitjan, D. F. (2017). Commentary on Mason et al. Clinical Trials, 14, (4), 368-9. Mason, A. J., Gomes, M., Grieve, R., Ulug, P., Powell, J. T., and Carpenter, J. (2017). Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE Trial. Clinical Trials, 14, (4), 357-67, DOI: 10.1177/1740774517711442.

Molenberghs, G., Fitzmaurice, G., Kenward, M. G., Tsiastis, A., and Verbeke, G. (ed.) (2015). Handbook of Missing Data Methodology. Chapman & Hall.

 Walters, S. J. and Brazier, J. E. (2005).
Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res*, 14, (6), 1523–32.

(日) (日) (日) (日) (日) (日) (日)